Abstract Number: 2718 • 2015 ACR/ARHP Annual Meeting
Along Those Lines: Synoviocyte Cell-to-Cell Communication Via Nanotubes
Background/Purpose: The synovium is primarily formed by fibroblast-like synoviocytes (FLS). Its multicellularity requires precise coordination to generate a tissue that confers specialized functions critical to…Abstract Number: 2719 • 2015 ACR/ARHP Annual Meeting
Track Along: Monocytes Follow Fibroblast-like Synoviocyte Network for Movement and Rest within the Synovial Tissue
Background/Purpose: The synovial lining tissue consists of fibroblast-like synoviocytes (FLS) and monocyte-derived macrophage-like synoviocytes (MLS) within a self-built meshwork of dense extracellular matrix (ECM) components.…Abstract Number: 2720 • 2015 ACR/ARHP Annual Meeting
Crucial Role of Nuclear Factor of Activated T Cell 5 (NFAT5), an Osmo-Protective Factor, in Migration and Invasion of Rheumatoid Synoviocytes
Background/Purpose: Fibroblast-like synoviocytes (FLS) play an important role in the progression of rheumatoid arthritis (RA). Particularly, FLS of RA patients (RA-FLS) exhibit pro-migratory and invasive…Abstract Number: 2721 • 2015 ACR/ARHP Annual Meeting
Elevated Subgingival Levels of Periodontal Pathogens in Rheumatoid Arthritis Patients, Particularly Leptotrichia species in New-Onset Disease
Background/Purpose: Periodontitis, a polymicrobial infectious and inflammatory disease of tooth-supporting structures, shares pathogenic mechanisms with rheumatoid arthritis (RA) and may trigger its onset. Most studies…Abstract Number: 2722 • 2015 ACR/ARHP Annual Meeting
Cyclic Phosphatidic Acid (CPA) Suppresses Expression of Cartilage Degrading Enzymes Such As MMP-3, MMP-13 and Adamts-4 in Inflammatory Synovial Fibroblasts and Articular Chondrocytes Induced By IL-1 Beta and/or TNF ALFA
Background/Purpose: Cyclic phosphatidic acid (cPA) is one of bioactive lipid, has been implicated as an mediator of various biological effects including inhibitory effects of proliferation,…Abstract Number: 2723 • 2015 ACR/ARHP Annual Meeting
Basal STAT5 Signaling Is Elevated in Multiple Peripheral Blood Cell Subsets in Rheumatoid Arthritis and Is Markedly Downregulated By IFN-γ in T Lymphocytes
Background/Purpose: The importance of type I interferons (IFN-α and others) as a driver of pathogenesis in autoimmunity, including rheumatoid arthritis (RA) is well recognized. However,…Abstract Number: 2724 • 2015 ACR/ARHP Annual Meeting
Methotrexate Treatment Could Modulate the Abnormal CD4+T Lymphocyte Subset Distribution in NaÏve Rheumatoid Arthritis Patients
Background/Purpose: Mechanisms regulating the chronic autoimmune response in rheumatoid arthritis (RA) are not well understood. However, activated T CD4+ play a pivotal role initiating and…Abstract Number: 2725 • 2015 ACR/ARHP Annual Meeting
Secular Trends in Use of Disease Modifying Anti-Rheumatic Drugs for the Treatment of Rheumatoid Arthritis in the United States
Background/Purpose: Treatment of rheumatoid arthritis (RA) with disease modifying anti-rheumatic drugs (DMARDs) has undergone major advances in last two decades. More than 10 non-biologic DMARDs…Abstract Number: 2726 • 2015 ACR/ARHP Annual Meeting
The Effect of Prior Disease Duration and Prior DMARD Use on Treatment Outcomes in Patients with Early or Established Rheumatoid Arthritis
Background/Purpose: A delay in effective treatment is known to negatively affect long term treatment outcomes in patients (pts) with rheumatoid arthritis (RA). The purpose of…Abstract Number: 2727 • 2015 ACR/ARHP Annual Meeting
BI 695501, a Proposed Biosimilar for Adalimumab, Shows Bioequivalence to Adalimumab Reference Products in a Randomized, Double-Blind Phase I Trial in Healthy Subjects
Background/Purpose: BI 695501 is a proposed adalimumab biosimilar currently in development and was evaluated for pharmacokinetic (PK) similarity to both US-licensed and EU-approved reference products.…Abstract Number: 2728 • 2015 ACR/ARHP Annual Meeting
Baseline Characteristics and Changes in Disease Activity at 12 Months in Patients Treated with Abatacept Versus Other Biologic Disease-Modifying Antirheumatic Drugs in Clinical Practice Setting
Background/Purpose: Biologic (b)DMARDs have advanced the standard of care in RA, reducing unmet needs and increasing remission rates. Abatacept (ABA) is approved for the management…Abstract Number: 2729 • 2015 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…Abstract Number: 2730 • 2015 ACR/ARHP Annual Meeting
Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
Background/Purpose: Baricitinib (bari) is an oral Janus kinase (JAK) 1 /JAK2 selective inhibitor, representing a potentially effective treatment for patients with moderately to severely active rheumatoid…Abstract Number: 2731 • 2015 ACR/ARHP Annual Meeting
Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry
Background/Purpose: For patients with rheumatoid arthritis (RA), there are limited real-world data on factors that predict persistency on biologic therapy or whether use of biologics…Abstract Number: 2732 • 2015 ACR/ARHP Annual Meeting
The Effect of Adrenocorticotropin Gel (HP Acthar Gel) in Combination with MTX in Newly Diagnosed RA Patients from a Clinical and Structural Perspective
Background/Purpose: Although adrenocorticotropin (ACTH) gel was approved by the FDA for the treatment of RA in 1952, data on its clinical and structural benefits for…
ACR Meeting Abstracts